Donatienne Van Weehaeghe1, Jenny Ceccarini1, Aline Delva2, Wim Robberecht3, Philip Van Damme4, Koen Van Laere. 1. Division of Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven and KU Leuven, Leuven, Belgium. 2. Department of Neurology, University Hospitals Leuven, Leuven, Belgium. 3. Department of Neurology, University Hospitals Leuven, Leuven, Belgium Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven-University of Leuven, Leuven, Belgium; and. 4. Department of Neurology, University Hospitals Leuven, Leuven, Belgium Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven-University of Leuven, Leuven, Belgium; and Laboratory of Neurobiology, VIB, Vesalius Research Center, Leuven, Belgium.
Abstract
UNLABELLED: An objective biomarker for early identification and accurate differential diagnosis of amyotrophic lateral sclerosis (ALS) is lacking. (18)F-FDG PET brain imaging with advanced statistical analysis may provide a tool to facilitate this. The objective of this work was to validate volume-of-interest (VOI) and voxel-based (using a support vector machine [SVM] approach) (18)F-FDG PET analysis methods to differentiate ALS from controls in an independent prospective large cohort, using a priori-derived classifiers. Furthermore, the prognostic value of (18)F-FDG PET was evaluated. METHODS: A prospective cohort of patients with a suspected diagnosis of a motor neuron disorder (n = 119; mean age ± SD, 61 ± 12 y; 81 men and 38 women) was recruited. One hundred five patients were diagnosed with ALS (mean age ± SD, 61.0 ± 12 y; 74 men and 31 women) (group 2), 10 patients with primary lateral sclerosis (mean age ± SD, 55.5 ± 12 y; 3 men and 7 women), and 4 patients with progressive muscular atrophy (mean age ± SD, 59.2 ± 5 y; 4 men). The mean disease duration of all patients was 15.0 ± 13.4 mo at diagnosis, with PET conducted 15.2 ± 13.3 mo after the first symptoms. Data were compared with a previously gathered dataset of 20 screened healthy subjects (mean age ± SD, 62.4 ± 6.4 y; 12 men and 8 women) and 70 ALS patients (mean age ± SD, 62.2 ± 12.5 y; 44 men and 26 women) (group 1). Data were spatially normalized and analyzed on a VOI basis (statistical software (using the Hammers atlas) and voxel basis using statistical parametric mapping. Discriminant analysis and SVM were used to classify new cases based on the classifiers derived from group 1. RESULTS: Compared with controls, ALS patients showed a nearly identical pattern of hypo- and hypermetabolism in groups 1 and 2. VOI-based discriminant analysis resulted in an 88.8% accuracy in predicting the new ALS cases. For the SVM approach, this accuracy was 100%. Brain metabolism between ALS and primary lateral sclerosis patients was nearly identical and not separable on an individual basis. Extensive frontotemporal hypometabolism was predictive for a lower survival using a Kaplan-Meier survival analysis (P < 0.001). CONCLUSION: On the basis of a previously acquired training set, (18)F-FDG PET with advanced discriminant analysis methods is able to accurately distinguish ALS from controls and aids in assessing individual prognosis. Further validation on multicenter datasets and ALS-mimicking disorders is needed to fully assess the general applicability of this approach.
UNLABELLED: An objective biomarker for early identification and accurate differential diagnosis of amyotrophic lateral sclerosis (ALS) is lacking. (18)F-FDG PET brain imaging with advanced statistical analysis may provide a tool to facilitate this. The objective of this work was to validate volume-of-interest (VOI) and voxel-based (using a support vector machine [SVM] approach) (18)F-FDG PET analysis methods to differentiate ALS from controls in an independent prospective large cohort, using a priori-derived classifiers. Furthermore, the prognostic value of (18)F-FDG PET was evaluated. METHODS: A prospective cohort of patients with a suspected diagnosis of a motor neuron disorder (n = 119; mean age ± SD, 61 ± 12 y; 81 men and 38 women) was recruited. One hundred five patients were diagnosed with ALS (mean age ± SD, 61.0 ± 12 y; 74 men and 31 women) (group 2), 10 patients with primary lateral sclerosis (mean age ± SD, 55.5 ± 12 y; 3 men and 7 women), and 4 patients with progressive muscular atrophy (mean age ± SD, 59.2 ± 5 y; 4 men). The mean disease duration of all patients was 15.0 ± 13.4 mo at diagnosis, with PET conducted 15.2 ± 13.3 mo after the first symptoms. Data were compared with a previously gathered dataset of 20 screened healthy subjects (mean age ± SD, 62.4 ± 6.4 y; 12 men and 8 women) and 70 ALSpatients (mean age ± SD, 62.2 ± 12.5 y; 44 men and 26 women) (group 1). Data were spatially normalized and analyzed on a VOI basis (statistical software (using the Hammers atlas) and voxel basis using statistical parametric mapping. Discriminant analysis and SVM were used to classify new cases based on the classifiers derived from group 1. RESULTS: Compared with controls, ALSpatients showed a nearly identical pattern of hypo- and hypermetabolism in groups 1 and 2. VOI-based discriminant analysis resulted in an 88.8% accuracy in predicting the new ALS cases. For the SVM approach, this accuracy was 100%. Brain metabolism between ALS and primary lateral sclerosispatients was nearly identical and not separable on an individual basis. Extensive frontotemporal hypometabolism was predictive for a lower survival using a Kaplan-Meier survival analysis (P < 0.001). CONCLUSION: On the basis of a previously acquired training set, (18)F-FDG PET with advanced discriminant analysis methods is able to accurately distinguish ALS from controls and aids in assessing individual prognosis. Further validation on multicenter datasets and ALS-mimicking disorders is needed to fully assess the general applicability of this approach.
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: Donatienne Van Weehaeghe; Martijn Devrome; Michel Koole; Koen Van Laere; Georg Schramm; Joke De Vocht; Wies Deckers; Kristof Baete; Philip Van Damme Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-20 Impact factor: 9.236
Authors: Marta Casquero-Veiga; Ravit Hadar; Javier Pascau; Christine Winter; Manuel Desco; María Luisa Soto-Montenegro Journal: PLoS One Date: 2016-12-29 Impact factor: 3.240
Authors: Paul Blanc-Durand; Axel Van Der Gucht; Eric Guedj; Mukedaisi Abulizi; Mehdi Aoun-Sebaiti; Lionel Lerman; Antoine Verger; François-Jérôme Authier; Emmanuel Itti Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240
Authors: M-S Buhour; F Doidy; A Mondou; A Pélerin; L Carluer; F Eustache; F Viader; B Desgranges Journal: EJNMMI Res Date: 2017-03-06 Impact factor: 3.138
Authors: Aline Delva; Nimish Thakore; Erik P Pioro; Koen Poesen; Rachel Saunders-Pullman; Inge A Meijer; Janet C Rucker; John T Kissel; Philip Van Damme Journal: Muscle Nerve Date: 2017-05-15 Impact factor: 3.217
Authors: Eoin Finegan; Rangariroyashe H Chipika; Stacey Li Hi Shing; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Colette Donaghy; Russell L McLaughlin; Niall Pender; Orla Hardiman; Peter Bede Journal: J Neurol Date: 2019-07-19 Impact factor: 4.849